Evidence map›Paper›PMID 28962233›Full record

ArticleToxicology reports2014

Comparison between the mainstream smoke of eleven RYO tobacco brands and the reference tobacco 3R4F.

A Marcilla, M I Beltran, A Gómez-Siurana, D Berenguer, I Martínez-Castellanos

Open access · goldAbstract read
In one paragraph

Article in Toxicology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Mainstream smoke constituents andToxicology reports · 2019
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

A MarcillaDepartamento Ingeniería Química, Universidad de Alicante, Apdo. 99, 03080 Alicante, Spain.
M I BeltranDepartamento Ingeniería Química, Universidad de Alicante, Apdo. 99, 03080 Alicante, Spain.
A Gómez-SiuranaDepartamento Ingeniería Química, Universidad de Alicante, Apdo. 99, 03080 Alicante, Spain.
D BerenguerDepartamento Ingeniería Química, Universidad de Alicante, Apdo. 99, 03080 Alicante, Spain.
I Martínez-CastellanosDepartamento Ingeniería Química, Universidad de Alicante, Apdo. 99, 03080 Alicante, Spain.
University of Alicante · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study 11 commercial roll-your-own (RYO) tobacco brands sold in Spain and the reference tobacco 3R4F have been smoked and several components of the mainstream tobacco smoke have been analyzed. Cigarettes were prepared using commercial tubes, and were smoked under smoking conditions based on the ISO 3308. The gaseous and condensed fractions of the smoke from RYO brands and 3R4F have been analyzed and compared. RYO tobaccos, as opposed to 3R4F, present lower amounts of condensed products in the traps than in the filters. In general, RYO tobaccos also provide lower yields of most of the compounds detected in the gas fraction. The yield of CO is between 15.4 and 20.4 mg/cigarette. In most of the cases studied, RYO tobaccos deliver higher amounts of nicotine than the 3R4F tobacco. On average, the yield of the different chemical families of compounds appearing in the particulate matter retained in the cigarette filters tends to be around three times higher than those obtained from 3R4F, whereas similar values have been obtained in the particulate matter retained in the traps located after the filters. It can be concluded that RYO tobaccos are not less hazardous than the reference tobacco, which may be contrary to popular belief.

Indexed as

COMainstream smokeNicotineRYO tobaccoTar

Identifiers

PMID28962233
PMCPMC5598218
OpenAlexW2136101645

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.